BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, Genge A, Miller R, Baloh RH, Kern R, Gothelf Y, Lebovits C, Cudkowicz M. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve 2020;62:156-66. [PMID: 31899540 DOI: 10.1002/mus.26801] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol 2020;33:655-61. [PMID: 32796282 DOI: 10.1097/WCO.0000000000000861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lamas NJ, Roybon L. Harnessing the Potential of Human Pluripotent Stem Cell-Derived Motor Neurons for Drug Discovery in Amyotrophic Lateral Sclerosis: From the Clinic to the Laboratory and Back to the Patient. Front Drug Discov 2021;1:773424. [DOI: 10.3389/fddsv.2021.773424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Cappella M, Pradat PF, Querin G, Biferi MG. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy. J Neuromuscul Dis 2021;8:25-38. [PMID: 33074186 DOI: 10.3233/JND-200531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Cunha-Oliveira T, Carvalho M, Sardão V, Ferreiro E, Mena D, Pereira FB, Borges F, Oliveira PJ, Silva FSG. Integrative Profiling of Amyotrophic Lateral Sclerosis Lymphoblasts Identifies Unique Metabolic and Mitochondrial Disease Fingerprints. Mol Neurobiol 2022. [PMID: 35933467 DOI: 10.1007/s12035-022-02980-7] [Reference Citation Analysis]
5 Daghlas SA, Govindarajan R; Pooled Resource Open-Access ALS Clinical Trials Consortium. Relative effects of forced vital capacity and ALSFRS-R on survival in ALS. Muscle Nerve 2021;64:346-51. [PMID: 34076262 DOI: 10.1002/mus.27344] [Reference Citation Analysis]
6 Béland LC, Markovinovic A, Jakovac H, De Marchi F, Bilic E, Mazzini L, Kriz J, Munitic I. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. Brain Commun 2020;2:fcaa124. [PMID: 33134918 DOI: 10.1093/braincomms/fcaa124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Murdock BJ, Goutman SA, Boss J, Kim S, Feldman EL. Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner. Neurol Neuroimmunol Neuroinflamm 2021;8:e953. [PMID: 33531377 DOI: 10.1212/NXI.0000000000000953] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Teixeira MI, Lopes CM, Gonçalves H, Catita J, Silva AM, Rodrigues F, Amaral MH, Costa PC. Formulation, Characterization, and Cytotoxicity Evaluation of Lactoferrin Functionalized Lipid Nanoparticles for Riluzole Delivery to the Brain. Pharmaceutics 2022;14:185. [PMID: 35057079 DOI: 10.3390/pharmaceutics14010185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Helleman J, Johnson B, Holdom C, Hobson E, Murray D, Steyn FJ, Ngo ST, Henders A, Lokeshappa MB, Visser-Meily JMA, van den Berg LH, Hardiman O, Beelen A, McDermott C, van Eijk RPA. Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: an international survey. J Neurol 2022. [PMID: 35849154 DOI: 10.1007/s00415-022-11273-x] [Reference Citation Analysis]
10 Ahmed N, Baker M, Bashford J. The landscape of neurophysiological outcome measures in ALS interventional trials: a systematic review. Clinical Neurophysiology 2022. [DOI: 10.1016/j.clinph.2022.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, Genge A, Miller R, Baloh RH, Kern R, Gothelf Y, Lebovits C, Cudkowicz M. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve 2020;62:156-66. [PMID: 31899540 DOI: 10.1002/mus.26801] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
12 Thome J, Steinbach R, Grosskreutz J, Durstewitz D, Koppe G. Classification of amyotrophic lateral sclerosis by brain volume, connectivity, and network dynamics. Hum Brain Mapp 2022;43:681-99. [PMID: 34655259 DOI: 10.1002/hbm.25679] [Reference Citation Analysis]
13 Witzel S, Frauhammer F, Steinacker P, Devos D, Pradat PF, Meininger V, Halbgebauer S, Oeckl P, Schuster J, Anders S, Dorst J, Otto M, Ludolph AC. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl Neurodegener 2021;10:31. [PMID: 34433481 DOI: 10.1186/s40035-021-00257-y] [Reference Citation Analysis]
14 Sun C, Fournier CN, Ye S, Zhang N, Ma Y, Fan D. Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale. Eur J Neurol 2021;28:1876-83. [PMID: 33686758 DOI: 10.1111/ene.14811] [Reference Citation Analysis]
15 Nam JY, Lee TY, Kim K, Chun S, Kim MS, Shin JH, Sung JJ, Kim BJ, Kim BJ, Oh KW, Kim KS, Kim SH. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. Trials 2022;23:415. [PMID: 35585556 DOI: 10.1186/s13063-022-06327-4] [Reference Citation Analysis]
16 Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, Williams TL, Chataway J, Swingler R, Parmar MKB, Stallard N, Weir CJ, Parker RA, Chaouch A, Hamdalla H, Ealing J, Gorrie G, Morrison I, Duncan C, Connelly P, Carod-Artal FJ, Davenport R, Reitboeck PG, Radunovic A, Srinivasan V, Preston J, Mehta AR, Leighton D, Glasmacher S, Beswick E, Williamson J, Stenson A, Weaver C, Newton J, Lyle D, Dakin R, Macleod M, Pal S, Chandran S. Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun 2021;3:fcab242. [PMID: 34901853 DOI: 10.1093/braincomms/fcab242] [Reference Citation Analysis]
17 Fournier CN. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design. Neurotherapeutics 2022. [PMID: 35819713 DOI: 10.1007/s13311-022-01271-2] [Reference Citation Analysis]
18 Beaulieu D, Berry JD, Paganoni S, Glass JD, Fournier C, Cuerdo J, Schactman M, Ennist DL. Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotroph Lateral Scler Frontotemporal Degener 2021;22:22-32. [PMID: 34348539 DOI: 10.1080/21678421.2021.1924207] [Reference Citation Analysis]
19 Quek H, Cuní-lópez C, Stewart R, Colletti T, Notaro A, Nguyen TH, Sun Y, Guo CC, Lupton MK, Roberts TL, Lim YC, Oikari LE, La Bella V, White AR. ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression. J Neuroinflammation 2022;19. [DOI: 10.1186/s12974-022-02421-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
20 Tornese P, Lalli S, Cocco A, Albanese A. Review of disease-modifying drug trials in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2022;93:521-9. [PMID: 35228271 DOI: 10.1136/jnnp-2021-328470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Cunha-Oliveira T, Silva DF, Segura L, Baldeiras I, Marques R, Rosenstock T, Oliveira PJ, Silva FSG. Redox profiles of amyotrophic lateral sclerosis lymphoblasts with or without known SOD1 mutations. Eur J Clin Invest 2022;:e13798. [PMID: 35467758 DOI: 10.1111/eci.13798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Bailey J. Biomedical Research Must Change - But a Shift Toward Human-specific Research Methods Is Only Part of What Is Needed. Altern Lab Anim 2021;:2611929211030417. [PMID: 34250842 DOI: 10.1177/02611929211030417] [Reference Citation Analysis]